A study looking at V940 immunotherapy with pembrolizumab for people with high risk melanoma (INTerpath-001)

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma. Each V940 treatment is made individually for each person taking part.

It’s for people who have:

• had all their melanoma removed with surgery and

• not had any other cancer treatment for their melanoma